Application of long noncoding RNA AC107398.2 in the prognosis of acute myeloid leukemia
By analyzing the survival curve and ceRNA network of AML patients, the prognostic value of LncRNA AC107398.2 in AML was studied, and it was found that its high expression was related to higher survival, revealing its mutual interaction with CD48, TRAT1, miR-9, etc. The path of action solves the shortcomings of AC107398.2 in the prognostic evaluation of AML in the prior art, and determines it as a stable biomarker of AML.
Patent Information
- Application Number
- CN202111546803.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-16
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-12-16
AI Technical Summary
In the prognostic evaluation of acute myeloid leukemia (AML), the existing technology has not fully utilized the role of long-chain non-coding RNA (LncRNA) in diseases, especially the clinical relevance and prognostic value of AC107398.2 in AML patients. Fully reveal.
By analyzing the survival curves of AML patients and building a ceRNA network, the clinical correlation and prognostic value of LncRNA AC107398.2 in AML were studied, and the differences between its high-expression and low-expression groups were found, and differential genes and ceRNA network analysis were combined with differential genes and ceRNA network analysis. , revealing the interaction paths of AC107398.2 with CD48, TRAT1, miR-9, etc.
The results show that AC107398.2 is a stable biomarker of AML prognosis. Its high expression is related to higher overall survival and event-free survival. Its expression independently predicts the survival of AML and is not affected by the treatment mode, indicating that it The adjustment function in AML may be implemented through the core axis MSI889/TRAT1-mir9-AC107398.2.
Smart Images

Figure CN114220517B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of leukemia prognosis assessment, and in particular to the application of long-chain non-coding RNA AC107398.2 in the prognosis of acute myeloid leukemia. Background Art
[0002] Acute myeloid leukemia (AML) is a genetically diverse hematopoietic malignancy with a poor prognosis and high mortality. To date, the prognostic significance of its molecular genetic alterations has been extensively studied. For example, the predictive value of CEBPA double mutation, FLT3-ITD, MLL partial tandem duplication (MLL-PTD), BAALC expression, and NPM1 mutation is well recognized. In recent years, the dysregulation of long noncoding RNAs (lncRNAs) in cancer has been recognized as a frequent event in cancer. In leukemia, lncRNA-HOTTIP aberrations, as an oncogenic event, interfere with HSC function by reprogramming leukemia-associated chromatin and gene transcription. LncRNA-H19 targets miR-29a-3p to promote proliferation of acute myeloid leukemia cells and inhibit apoptosis through the Wnt / β-catenin signaling pathway. LncRNA-CCDC26 is also a new biomarker that can predict the prognosis of acute myeloid leukemia. Overexpression of lncRNA PANDAR predicts poor prognosis in acute myeloid leukemia. However, the oncogenic roles of a large number of LncRNAs remain to be elucidated. Summary of the invention
[0003] The present invention studies the clinical relevance and prognostic value of LncRNA AC107398.2 in acute myeloid leukemia by analyzing the survival curves of AML patients and constructing a ceRNA network, and preliminarily reveals its potential mechanism and application.
[0004] The results showed that in the chemotherapy and transplantation groups, AML patients with high expression of AC107398.2 had a higher overall survival than those with low expression of AC107398.2. Therefore, AC107398.2 is a stable biomarker for the prognosis of acute leukemia AML. Differential gene and ceRNA network analysis showed that AC107398.2, together with protein-coding genes CD48, TRAT1, and microRNA miR-9, miR-136, constitute a pathway regulating AML disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0005] Figure 1 The effect of long noncoding RNA-AC107398.2 on the prognosis of acute myeloid leukemia - Kaplan–Meier survival curves of overall survival and event-free survival;
[0006] Figure 2Differential gene analysis and ceRNA network analysis were performed for the AC107398.2 high expression group and AC107398.2 low expression group. DETAILED DESCRIPTION
[0007] In order to make the technical problems to be solved, technical solutions and advantages of the present invention more clear, they are described in detail below in conjunction with specific embodiments.
[0008] 1. Materials and Methods
[0009] Study Cohort
[0010] Transcriptome sequencing datasets and corresponding clinical information of 151 AML cohorts were downloaded from the TCGA (https: / / www.cancer.gov / ) database. After excluding 15 M3 patients, a total of 136 patients with AC107398.2 expression data were included in the subsequent analysis. In addition, the microRNA sequencing data of the remaining 136 patients were also downloaded from the TCGA database for subsequent analysis. The clinical information of this cohort includes treatment methods, age, gender, white blood cell count (white blood cell, WBC), peripheral blood blasts (peripheral blood blasts, PB_blasts), bone marrow blasts (Bone Marrow blasts, BM_blasts), FAB typing and other characteristics. Based on the needs of the study, all patients signed informed consent.
[0011] Statistical analysis
[0012] Patients were grouped according to the median expression of AC107398.2. Clinical characteristics and related molecular characteristics of different groups were compared and analyzed using the Wilcoxon-Mann-Whitney test or the chi-square test depending on whether they were numerical variables or categorical variables. Overall survival and event-free survival analysis were performed using the Kaplan-Meier and log-rank tests. All graphics and statistical analyses were performed in R version 4.0.
[0013] Differential gene and ceRNA network analysis
[0014] In this study, differential gene analysis was performed using DESeq2, and the threshold for differential gene analysis was FDR < 0.01, |logFC| > 1. Metascape (http: / / metascape.org / ) was used for analysis and annotation of differential gene functional enrichment analysis. The ceRNA network was constructed using the GDCRNAtools tool.
[0015] GDCRNAtools uses three criteria to determine competitive endogenous interactions between lncRNA-mRNA pairs:
[0016] lncRNA and mRNA must share a large number of miRNAs; the expression of lncRNA and mRNA must be positively correlated; miRNA should play a similar role in regulating the expression of lncRNA and mRNA. Therefore, only the edges and nodes with hyperPValue>0.01, corPValue>0.01, and regSim=0 are retained.
[0017] result
[0018] 1. Comparison of clinical and molecular characteristics between AC107398.2 high expression group and AC107398.2 low expression group
[0019] According to the median expression of LncRNA-AC107398.2 in AML patients, 136 patients were divided into AC107398.2 high expression group and AC107398.2 low expression group, each group contained 68 patients, and their clinical characteristics and molecular characteristics are shown in Table 1. As shown in Table 1, the comparison of the clinical characteristics and molecular characteristics of the two groups of patients showed that the mutation frequency of the NPM1 gene in the AC107398.2 low expression group was significantly higher than that in the AC107398.2 high expression group (p = 0.036). The RUNX1 gene mutation appeared more frequently in the AC107398.2 high expression group (p = 0.029). There was no significant difference in the distribution of other clinical characteristics such as treatment method, age, gender, white blood cell count (WBC), peripheral blood blasts (PB_blasts), bone marrow blasts (BM_blasts) and other mutation characteristics such as FLT3-ITD, IDH1 / 2, etc. between the AC107398.2 high expression group and the AC107398.2 low expression group.
[0020] Table 1. Clinical and molecular characteristics of AML patients
[0021]
[0022]
[0023]
[0024] 2. Effect of long noncoding RNA AC107398.2 on the prognosis of acute myeloid leukemia (AML)
[0025] In order to analyze the effect of Lnc-RNA AC107398.2 on the prognosis of acute myeloid leukemia (AML), the Kaplan-Meier survival curves of overall survival (OS) and event-free survival (EFS) were prepared for two groups of patients divided into AC107398.2 high expression group and AC107398.2 low expression group according to the median expression of AC107398.2. Figure 1 shown. Figure 1 Middle: A) AML patients with high expression of AC107398.2 had a higher overall survival compared with AML patients with low expression (p=0.000298). B) AML patients with high expression of AC107398.2 had a higher event-free survival compared with AML patients with low expression (p=0.00219). C) In the group of AML patients who received chemotherapy alone, patients with high expression of AC107398.2 had a higher overall survival compared with patients with low expression (p=0.029). D) In the group of AML patients who received chemotherapy alone, there was no significant difference in event-free survival between patients with high expression of AC107398.2 and patients with low expression (p=0.0678). E) In the group of AML patients who received transplantation alone, patients with high expression of AC107398.2 had a higher overall survival compared with patients with low expression (p=0.0164). F) In the group of AML patients who received transplantation only, there was no significant difference in event-free survival between patients with high expression of AC107398.2 and those with low expression (p=0.128).
[0026] Kaplan-Meier survival analysis showed that AML patients with high expression of AC107398.2 had a longer overall survival than those with low expression (p=0.000298, Figure 1 (A) and event-free survival (p = 0.0219, Figure 1 (B). Further multivariate analysis showed that the expression of Lnc-RNA AC107398.2 was an independent predictor of AML event-free survival (p=0.038, Table 2) and overall survival (p=0, Table 2). In addition, multivariate analysis showed that treatment was also a very strong independent predictor of AML overall survival (p=0, Table 2).
[0027] Table 2. Multivariate analysis of OS and EFS in AML patients
[0028]
[0029] WBC: white blood cell count; PB blasts: plasma tumor cells; BM blasts: bone marrow tumor cells; coef: coefficient of control variable; HR: risk factor; CI: confidence interval.
[0030] In order to observe the effect of AC107398.2 expression level on the prognosis of different treatment methods, 70 patients who received only chemotherapy and 66 patients who received only bone marrow transplantation were further selected from the 136 patients. Figure 1 Kaplan–Meier survival curve analysis showed that in the group of AML patients who received chemotherapy only, patients with high expression of AC107398.2 had a longer overall survival than those with low expression (p=0.029, Figure 1 However, there was no significant difference in event-free survival (p = 0.0678, Figure 1 Similarly, in the group of AML patients who received only bone marrow transplantation, patients with high expression of AC107398.2 had a longer overall survival compared with patients with low expression (p = 0.0164, Figure 1 E), but there was no significant difference in event-free survival (p = 0.128, Figure 1 Middle F).
[0031] 3. Analysis of differentially expressed genes and ceRNA network
[0032] Then, differential gene analysis was performed on the AC107398.2 high expression group and AC107398.2 low expression group. A total of 40 up-regulated genes and 17 down-regulated genes were obtained in the AC107398.2 high expression group (such as Figure 2 Middle A, Figure 2 Functional enrichment analysis of differentially expressed genes showed that these genes were significantly enriched in signaling pathways such as bone marrow leukocyte activation, estrogen response, protein maturation, regulation of activated T cell proliferation, and endocytosis regulation ( Figure 2 In order to further understand the potential mechanism of AC107398.2 in AML, the ceRNA network related to AC107398.2 was constructed using GDCRNAtools. The results showed that AC107398.2 formed a ceRNA network with protein-coding genes CD48, TRAT1 and microRNA miR-9, miR-132, miR-150 in AML ( Figure 2 (middle D).
[0033] like Figure 2 Shown are differential gene analysis and ceRNA network analysis diagrams for AC107398.2 high expression group and AC107398.2 low expression group. Figure 2Middle: A) Volcano plot of differentially expressed genes in AC107398.2 high expression group and AC107398.2 low expression group (FDR<0.01, |logFC|>1B). B) Statistics of different types of differentially expressed genes, the horizontal axis is protein-coding genes, pseudogenes, TECs, long non-coding RNAs, and the vertical axis is the number of differentially expressed genes, red represents up-regulated genes, and blue represents down-regulated genes. C) Functional enrichment map of differentially expressed genes (p<0.01). D) ce-RNA network map.
[0034] in conclusion
[0035] The results showed that in the chemotherapy and transplantation groups, AML patients with high expression of AC107398.2 had a higher overall survival than AML patients with low expression. Therefore, AC107398.2 is a stable biomarker for the prognosis of patients with acute leukemia AML. Differential gene and ceRNA network analysis showed that AC107398.2, together with protein-coding genes CD48, TRAT1, and microRNA miR-9, miR-136, constitute a pathway for regulating AML disease. In other words, by regulating the expression of the above genes, the survival of AML patients is reversely regulated, and by stimulating the expression of genes such as AC107398.2, the survival of AML patients is prolonged.
[0036] discuss
[0037] The present invention has found through research that the mutation frequency of the NPM1 gene in the AC107398.2 low expression group is significantly higher than that in the AC107398.2 high expression group (p=0.036). The RUNX1 gene mutation is more frequent in the AC107398.2 high expression group (p=0.029). Studies have shown that patients with NPM1 mutations tend to have a longer survival, and RUNX1 mutations are an important predictor of shortened total lifespan. Therefore, it is suggested that the expression of AC107398.2 may have an impact on the prognosis of AML. Further analysis found that AML patients with high expression of AC107398.2 have a higher overall survival than AML patients with low expression. Currently, the main means of treating AML are chemotherapy and bone marrow transplantation, and bone marrow transplantation is a very effective means of treating AML, and patients who receive bone marrow transplantation generally have a longer survival period. The present invention further divides the patients into a chemotherapy group and a transplantation group. The results show that in the chemotherapy group, AML patients with high expression of AC107398.2 have a higher overall survival than AML patients with low expression. In the transplantation group, the effect of AC107398.2 on patient prognosis cannot be eliminated. AML patients with high expression of AC107398.2 also have a higher overall survival than AML patients with low expression. Further multivariate analysis shows that the expression of Lnc-RNA AC107398.2 is an independent predictor of AML event-free survival and overall survival. Therefore, high expression of AC107398.2 is a predictor of good prognosis of AML, and its predictive value will not be affected by the treatment methods received by the patient. AC107398.2 is a stable and independent biomarker for predicting AML prognosis.
[0038] Due to the lack of research on the potential mechanism of AC107398.2 in tumors. The present invention conducted differential gene analysis on AC107398.2 high expression and AC107398.2 expression groups in AML patients in the TCGA database. The results showed that these differential genes were enriched in signaling pathways such as bone marrow leukocyte activation, estrogen response, protein maturation, regulation of activated T cell proliferation, and endocytosis regulation. In order to further understand the function of lncRNA, we constructed the ceRNA network where AC107398.2 is located. It was found that AC107398.2 interacts with protein-coding genes CD48, TRAT1 and microRNA mir-9, mir-136, etc. In order to identify the core ceRNA network structure, we analyzed the prognosis and correlation of mRNA and miRNA in all ceRNA networks, and found that MSI889 / TRAT1-mir9-AC107398.2 is the core axis of AC107398.2 in AML regulation, with significant expression and prognosis-related patterns. MIS18BP1 (MIS18 binding protein 1) is a protein-coding gene, and its related pathways include chromosome maintenance, cell cycle, mitosis, etc. TRAT1 (T cell receptor-associated transmembrane adaptor 1) has been reported to be positively correlated with the survival rate of metastatic melanoma. Compared with the small number of studies on MIS18BP1 and TRAT1 in tumors, the function of miR-9 in tumors has been widely studied, and many studies have revealed the important role of miR-9 in the occurrence and development of blood diseases and malignant blood system diseases. Emmrich et al. showed that overexpression of miR-9 inhibited the differentiation and formation of AML cell lines with t(8;12) abnormalities. Tian et al. showed that miR-9 plays an important role in supporting the growth and survival of AML cells by downregulating Hes1, and miR-9 has the potential to be a therapeutic target for AML. In general, this study believes that the regulatory function of AC107398.2 in AML may be achieved through the core axis MSI889 / TRAT1-mir9-AC107398.2.
[0039] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of a biomarker in the preparation of a prognosis assessment detection product for patients with acute myeloid leukemia, wherein the biomarker is long non-coding RNA AC107398.
2.
2. The use according to claim 1, characterized in that: The prognosis assessment detection product includes a detection reagent for detecting the expression level of AC107398.
2.
3. The use according to claim 2, characterized in that: AML patients with high expression of AC107398.2 are predicted to have longer survival than AML patients with low expression of AC107398.
2.
4. Use of a biomarker in the preparation of a drug for the prognosis of AML patients by using AC107398.2 as a target to regulate its expression level, wherein the biomarker is long non-coding RNA AC107398.
2.
5. The use according to claim 4, characterized in that: The drug targets AC107398.2 and promotes its expression to prolong the survival of AML patients.
6. The use according to claim 4, characterized in that: AC107398.2 also co-regulates with protein-coding genes and / or microRNAs as targets.
7. The use according to claim 6, characterized in that: Protein coding genes include CD48 and / or TRAT1.
8. The use according to claim 6, characterized in that: The microRNA includes miR-9 and / or miR-136.
Citation Information
Patent Citations
Method and system for discovering utilization of ceRNA mechanism by long non-coding RNA molecular markers through multi-data platform and application
CN110415764A
Molecular marker Lnc-HEATR1-4 for diagnosis and prognosis of acute myeloid leukemia and application of molecular marker Lnc-HEATR1-4
CN113584174A
